Patient-Friendly Explanation

An experimental weight-loss medication taken as a daily pill rather than an injection. It works similarly to semaglutide (Ozempic/Wegovy) by targeting the GLP-1 hormone pathway, but may be more convenient since it does not require needles.

Clinical Definition

Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist currently in Phase 3 clinical trials. Unlike peptide-based GLP-1 agonists that require subcutaneous administration, its small-molecule structure enables oral bioavailability, with early trial data suggesting clinically meaningful weight reduction of 12 to 14 percent at 36 weeks.

Why It Matters

An effective oral GLP-1 medication could expand access to medical weight-loss treatment for patients who are needle-averse. At NuLifeCare Singapore, we stay current with emerging pharmacotherapy to offer you the most appropriate treatment options as they become available.